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Abstract  
Background: Elevated troponin level findings among patients presenting with suspected 
acute coronary syndrome (ACS) or another inter-current illness undeniably identifies 
patients at increased risk of mortality. Whilst enhancing our capacity to discriminate risk, 
the use of high-sensitivity troponin assays frequently identifies patients with myocardial 
injury (i.e. troponin rise without acute signs of myocardial ischaemia) or type 2 myocardial 
infarction (T2MI, oxygen supply-demand imbalance). This leads to the clinically 
challenging task of distinguishing type 1 myocardial infarction (T1MI, coronary plaque 
rupture), from myocardial injury and T2MI in the context of concurrent acute illness. 
Diagnostic discernment in this context is crucial as MI classification has implications for 
further investigation and care. Early invasive management is of well-established benefit 
among patients with T1MI. However, the appropriateness of this investigation in the 
heterogeneous context of T2MI, where there is high competing mortality risk remains 
unknown. Whilst coronary angiography in T2MI is advocated by some, there is insufficient 
evidence in existing literature to support this opinion as highlighted by current national 
guidelines.  
Objective: To evaluate the clinical and economic impact of early invasive management 
with coronary angiography in T2MI in terms of all-cause mortality and cost effectiveness. 
Design: This prospective, pragmatic, multi-centre, randomised trial among patients with 
suspected supply demand ischaemia leading to troponin elevation, (n=1800, T2MI [1500], 
chronic myocardial injury [300]) compares the impact of invasive angiography (or CT 
angiography as per local preference) within 5 days of randomization versus conservative 
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mortality by 2 years. Randomized treatment allocation will be stratified by baseline 
estimated risk of mortality using the APACHE III risk score. Cost-effectiveness will be 
evaluated by follow-up on clinical events, quality of life and resource utilization over 24 
months.  
Summary: Ascertaining the most appropriate first line investigative strategy for these 
commonly encountered high risk T2MI patients in a randomized comparative study will be 
pivotal in informing evidence-based guidelines that lead to better patient and health-care 
outcomes.  
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Introduction 
Complexity in the interpretation of cardiac myonecrosis, largely troponin, has led to the 
development of Universal Definitions of Myocardial Infarction (MI) conceptually classifies 
MI subgroups. (1) Diagnostic discrimination of these conceptual subgroups has 
implications for further management.  The advancement of high-sensitivity troponin assays, 
whilst enhancing our capacity to risk stratify patients, is however increasingly making 
subgroup differentiation a clinically challenging task.  Type 1 MI (T1MI), defined as a 
spontaneous MI due to coronary plaque rupture, has a strong evidence-base for the use of 
early invasive management (angiography ± revascularization) thus its use in this context is 
highly recommended and has become common practice. The management of type 2 MI 
(T2MI), defined as an MI resulting from myocardial nutrient demand and blood supply 
imbalance due to physiological or pathological stressors, and myocardial injury, 
rudimentally defined as elevated troponins without clincial signs of acute myocardial 
ischaemia, remains haphazard as a consequence of insufficient guiding evidence. (2-4)  
T2MI is associated with worse clinical outcomes and a much greater mortality rate than 
T1MI, even when accounting for precipitating illness and a degree of myocardial injury 
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Currently, practical differentiation of T2MI versus T1MI almost always relies on 
investigative coronary angiography to exclude or identify culprit coronary lesions 
(diagnosing T1MI) yet the appropriateness of coronary angiography among the T2MI 
patient population, where there is high concurrent competing risk of mortality from inter-
current illness and increased bleeding risk, remains uncertain and evidence validating the 
benefits of subsequent coronary interventions is lacking. (7,8) As such, management of 
T2MI remains highly variable, guideline recommendations are limited, and clinical 
equipoise persists. (9)    
To date, few studies formally integrating risk assessment into the strategy of coronary 
investigation have been undertaken. A randomised trial of routine early angiography versus 
conservative management that carefully evaluates baseline patient risks and competing 
risks is critical to the development of robust recommendations for these commonly 
encountered high morbidity and mortality patients.  
Methods 
Objectives and Hypotheses  
The primary objective of the study is to evaluate the impact of an early anatomic 
investigation of the coronary arteries on 24-month all-cause survival among T2MI patients 
within a pragmatic multi-centre randomised clinical trial. Secondary objectives are to 
examine the ECG, echocardiographic and biomarker characteristics, and patient competing 
risk profile associated with benefit from early coronary investigation with respect to late 
mortality. A third objective is to define the incremental cost-effectiveness of applying early 
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The primary hypothesis of this study is that knowledge of the coronary anatomy in T2MI 
leads to the use of therapies that result in an improvement in survival at 24 months. The 
secondary hypothesis is that the survival benefit associated with early anatomic 
investigation is determined by the degree to which cardiac risk is reduced relative to 
competing risks.  
 
Study Design 
This prospective open-labeled parallel clustered RCT with blinded endpoint assessment 
(PROBE) study is designed to couple objective competing-risk assessment in all eligible 
patients with the randomized allocation to anatomic coronary investigation or an 
conservative management. Patients (n=1800) will be randomised to either routine 
angiography (with further testing and coronary revascularization at clinician discretion) 
within 5 days versus conservative management (with functional testing at clinician 
discretion) (figure 2).  
Given this population's high comorbidity burden and competing cardiac and non-cardiac 
risks, the primary endpoint will be all-cause mortality (i.e. survival). Additionally, in order 
to focus on patients with a greater likelihood of supply-demand ischaemia, enrolment of 
patients with chronic myocardial injury (pattern 2: See “Standardized risk assessment and 
troponin pattern") will be capped at n=300 and outcomes will be exploratory in this 
subpopulation. Clinical events will be determined during 24-month follow-up. All enrolled 
patients will have their baseline Global Registries for Acute Cardiac Events (GRACE) risk 
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evaluated. (10,11) Block randomization will be undertaken within strata, based on troponin 
pattern, predicted risk of in-hospital mortality (APACHE III) and enrolling hospital. Aside 
from the allocated management strategy and assosciated timelines, all other subsequent 
management including secondary prevention therapies will be left to clinician discretion. 
The utility of clinical, echocardiographic and biomarkers in identifying patients with T2MI 
who may benefit from routine invasive management remains undefined thus uncertain, 
hence these sub-analyses will remain observational and exploratory. (Reg. No. 
ACTRN12618000378224p).  
Funding source and Authorship  
This research is supported by funding from the National Health and Medical Research 
Council of Australia (APP1146512). The authors are solely responsible for the design and 
condouct of this study, all study analyses, the drafting and editing of the paper and its final 
contents. 
 
Standardized Risk Assessment and Troponin Pattern 
Table 1 describes the patient eligibility criteria. The study will enrol in-hospital patients 
with at least one elevated (“rule-in”) troponin result (i.e. Troponin T (Roche Elecsys): 
>52ng/L and Troponin I (Abbott Architect, Dimension Vista, Beckman Access): ≥5 times 
the assay-specific upper limit of normal) using the local laboratory standards, presenting 
with an defined intercurrent illness.  These values have been selected to ensure a clinical 
population with heightened risk of recurrent cardiac events. Furthermore, the kinetics of the 
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1) Troponin Pattern 1 (Acute Myocardial Injury): A rise and/or fall in troponin from at 
least 2 samples defined as:  
a) Hs-Troponin T: A rise and/or fall in the absolute troponin level of 2.5ng/L/hour 
(i.e. a change of 15ng/L in 6 hours) between any troponin results before 
randomization OR a relative change in troponin 20% between earlier and later 
samples (i.e. 100*(hs-TnT[later] - hs-TnT[earlier])/hs-TnT[earlier] 20%) 
documented on any troponin results before randomization. (12,13) 
Hs-Troponin I: An absolute elevation of 10 times the upper limit of normal specific 
for that assay using gender-specific cut-points (i.e. Abbott Architect : 160ng/L for 
females and 260ng/L for males); OR change in troponin 20% between earlier and 
later samples (i.e. 100*(hs-TnI[later] - hs-TnI[earlier])/hs-TnI[earlier] 20%) 
documented on any troponin results before randomization. (14)  
2) Troponin Pattern 2 (Chronic Myocardial Injury): A stable elevation in the troponin 
requires at least 2 samples and defined as: 
a) Hs-Troponin T: A rise and/or fall in the absolute troponin level of <2.5ng/L/hour 
(i.e. a changed of <15ng/L in 6 hours) between all available troponin results prior to 
randomization; AND, a relative change in troponin <20% between earlier and later 
samples (i.e. 100*(hs-Tn[later] - hs-Tn[earlier])/hs-Tn[earlier] <20%) between all 
available troponin results prior to randomization with at least 2 troponin samples 
taken at least 3 hours apart. 
b) Hs-Troponin I: An absolute elevation of <10 times the upper limit of normal 
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<160ng/L for females and <260ng/L for males); AND a relative change in troponin 
<20% between earlier and later samples (i.e. 100*(hs-TnI[later] - hs-
TnI[earlier])/hs-TnI[earlier] <20%) any troponin results before randomization with 
at least 2 troponin samples taken at least 3 hours apart. 
All participants will have clinical symptomatology, ECGs, and all avalaible cardiac 
imaging assessed to determine the presence of coronary ischaemia. This information will 
permit the adjudication of the enrolling diagnosis as either type 2 MI or acute myocardial 
injury according to the 4
th
 Univsersal Definition of Myocardial Infarction. 
 
Recognizing the potential impact of the varying underlying hazards for mortality across 
different primary illnesses (i.e. competing risks), each patient's specific APACHE III 
prognostic score for in-hospital mortality will be calculated for use in discriminating low, 
intermediate and high baseline risk patients. A standard risk assessment pro forma will be 
used to provide detailed baseline risk stratification. This will include clinical components of 
the APACHE III, GRACE and Thrombolysis in Myocardial Infarction (TIMI) risk score, as 
well as documentation of left ventricular (LV) function, preexisting chronic conditions, and 
pre-morbid functional capacity using a 7 point frailty index assessing ability to perform 
daily activities. (10,11,15,16) Haematological and biochemical assessment will include 
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Randomized management strategies 
Based on baseline risk, patient randomization will occur in blocks of size 4 within predicted 
strata of <10%, 10-20% and >20% in-hospital mortality risk, thus enabling exploratory 
analysis of an interaction between the efficacy of angiography and the patient's baseline 
risk.  Furthermore, to ensure balance between troponin pattern and local hospital 
preferences for invasive coronary angiogram (ICA) versus CT coronary angiogram (CTCA) 
anatomic investigation, patients will be block randomized by site and troponin pattern at the 
time of enrolment.  
Consenting patients will be randomized to either:  
1) Routine Coronary Investigation undertaken within 5 days of randomization: If 
invasive  coronary angiography is selected as per local practice, radial or femoral 
access will be permitted. Revascularisation will be at the discretion of the treating 
team. Angiography undertaken outside the 5-day window will be considered a 
protocol violation, but these patients will be retained in the analysis. CTCA is an 
acceptable alternative to invasive angiography and may be the preferred modality in 
the enrolling institution. If undertaken as first line test, CTCA must be undertaken 
within the same time windows. (Subsequent progression to invasive angiography 
will be by physician discretion). 
2) Conservative management: Functional testing may be undertaken within the 14 day 
post randomization period as per local clinical decision. Functional testing may be 
either with ECG, stress echocardiography, nuclear perfusion scanning, or stress 
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Management crossover between conservative/functional testing and invasive 
angiography 
To minimize unwarranted crossover from conservative management to invasive 
investigation, the following criteria will be used to guide clinical decision-making 
regarding the use of angiographic investigation: 
1) Ongoing symptoms of angina (Canadian Cardiovascular Society (CCS) classification 
II-IV); or,  
2) The development of non-sustained or sustained ventricular tachycardia;  
3) Development of heart failure (New York Heart Association (NYHA) II-IV); or,  
4) Evidence of inducible ischaemia on functional testing where there is >10% of the 
myocardium deemed to be at risk.  Patients with abnormal or equivocal functional ECG 
testing should subsequently undergo functional testing with additional cardiac imaging.  
 
Data Collection and Outcome Measures 
The primary outcome will be all cause mortality (survival) up to 24 months. Major 
secondary clinical outcomes assessed at 30 days, 12 months and 24 months are defined in 
table 2. 
All patients will be followed to assess the frequency of diagnostic procedure(s)/service(s) at 
initial presentation and during follow-up (e.g. stress testing, echocardiography, invasive 
investigation and revascularization), inpatient costs/total length of stay (LOS), outpatient 
health care attendance(s) (i.e. general practitioner and specialist attendances), 
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indicated. At 30 days, 12 months and 24 months, patients will be contacted by telephone 
and assessed for vital status, rehospitalisation and quality of life (EuroQoL 5 dimensions 5 
levels (EQ-5D-5L)). (17)In hospital costs will be sourced from hospital billing systems, 
while outpatient costs will be determined through the national Medical Benefits Schedule 
and Prescribing Benefits Schedule (i.e. Australia's nationalized health funding system) 
 
Ethical Considerations and Study Governance 
All patients will be asked to provide written informed consent. Primary approval has been 
granted by the local Clinical Human Research Ethics Committee. The Steering Committee, 
consisting of cardiologists, general physicians and implementation experts, will provide 
oversight to the study. A Clinical Event Adjudication Committee, independent of the study 
management team, will be providing blinded evaluation (events de-identified for treatment 
arm, hospital and patient details) of the primary and secondary endpoints.  The study 
employs a Data Safety Monitoring Board (DSMB) to ensure patient safety, leveraging the 
existing administrative data infrastructure to facilitate event adjudication.  This is an 
investigator-initiated study funded by the National Health and Medical Research Council of 
Australia (APP1146512).  
Sample Size Determination 
All sample size calculations assume a Type I and II error rates of 5% and 20%, 
respectively. Given the substantial all-cause mortality rate among these patients, design 
assumptions have been expressly chosen to detect a clinically relevant improvement in 
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cause mortality rate of 41% by 12 months (from SA Hospitals 2009-2011). A baseline 
survival rate of 70% by 2-year has been assumed and this study is designed to detect an 
absolute increase in survival of 7% by 2 years with the anatomic investigation strategy (i.e. 
a relative increase in survival within the coronary investigation arm of 10% [Hazard ratio: 
0.73]) in the patients with T2MI [troponin pattern 1] which translates to a number needed to 
treat (NNT) of 14.  Consequently, accounting for lost to follow-up rate of 3%, the study 
will enrol 1500 patients. The effect of early coronary investigation among patients with 
pattern 2 (n=300) is exploratory. 
 
Methods of Statistical Analyses 
The primary analysis population will be intention-to-treat including all patients randomised 
to the study and reported according to CONSORT guidelines.  Missing data will be 
imputed using multiple imputations, redrawing 20 samples.  Sensitivity analyses will also 
be conducted per-protocol (i.e. primary comparison included only those patients receiving 
their randomized allocation).  
The primary analysis will compare the survival time (freedom from the primary endpoint  
of all-cause mortality) between the routine coronary anatomical and conservative/functional 
testing arms using log-rank testing within the population randomised within the Troponin 
Pattern 1 criteria (i.e. Troponin pattern 1 intention-to-treat (ITT) population [target 
N=1500]). Major secondary analyses will evaluate the study arms with respect to survival 
time free from the primary endpoint: within the entire population (I.e. Troponin patterns 1 
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interaction between the enrolling troponin pattern and the study arms. These analyses will 
also be undertaken evaluating the endpoint of two-year freedom from mortality and 
recurrent cardiovascular events by survival analysis using shared frailty models to account 
for correlated event rates within hospitals. An exploratory subgroup analysis base on initial 
coronary investigation (i.e. CTCA versus ICA) will also be undertaken. 
An economic evaluation comparing mean outcomes and incremental costs of invasive 
angiography to those for conservative management will be conducted. This evaluation will 
take the form of a cost-utility analysis with the primary outcome expressed as incremental 
costs per quality adjusted life year (QALY) gained over 24 months. To calculate QALYs, 
patient level measures of utility derived from the EQ-5D 5L instrument will be integrated 
with survival curves using the quality-adjusted survival analysis (QASA) method. (18) 
Incremental costs associated with both trial arms will be estimated using patient data 
obtained from the Medical Benefits Scheme (MBS), Pharmaceutical Benefits Scheme 
(PBS) and Australian Refined Diagnosis Related Group (AR-DRG) cost weights. 
Bootstrapped mean costs and outcomes between the intervention and control groups will be 
compared, and incremental cost effectiveness ratios (ICERs) presented with confidence 
intervals. Uncertainty in the economic evaluation results will be taken account of through 
appropriate one-way and multi-way sensitivity analyses. 
 
Discussion 
To optimally evaluate the unbiased impact of routine assessment of coronary anatomy on 
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observational designs with inadequate correction of selection bias often have a strong 
impact on outcomes. Prospective randomization and blinded event adjudication provides 
the most practical and least biased estimate and strategy effect. The endpoint of all-cause 
mortality has been chosen as it is considered most patient-relevant when weighing both 
cardiac and non-cardiac risks. Standardized evaluation of the pre-test probability of non-
coronary risk through the APACHE III score will inform the clinical translation of these 
results within the routine care of patients with greatly varied risk. Independent and blinded 
adjudication of the admission (index) diagnosis and clinical events will provide a robust 
evaluation of the clinical relevance of routine coronary investigation for myocardial injury 
and type 2 MI. 
Previous research demonstrates that  mortality among patients with T2MI often occurs 
early following the index event, akin to T1MI, but with a constant and elevated recurrent 
MI risk over time in contrast to decreasing rates of recurrent MI within weeks to months 
after the index event in T1MI. This pattern would be consistent with a “non-plaque rupture” 
mechanism. (5) Data from the SWEDEHEART registry (n=20,138) corroborates the 
substantial increase in mortality within this population. Compared with T1MI, T2MI was 
also associated with much lower rates of ICA (35.9% vs. 77.3%, p<0.001), anti-platelet 
therapy and secondary prevention pharmacologies, and a crude increased hazard for 
mortality (HR:1.86 [95% C.I. 1.6 6 to 2.08])  by 12 months. (6) Importantly, after adjusting 
for baseline differences in clinical characteristics and in-hospital management, there was no 
longer any difference in 12-month all-cause mortality (HR: 1.03 [95% C.I. 0.86 to 1.23]) 
between T2MI and T1MI. This observation suggests the potential value of applying 
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risk T2MI population. The value of routine invasive management among patients with 
competing non-cardiac risks however remains unclear. Figure 3 describes the interaction 
between the patient risk profile and diagnostic clarity (with implications for the provision 
of evidence based therapies) across the spectrum of possible manifestations of coronary 
artery disease.  
Within this paradigm, patients presenting with myocardial injury and T2MI represent the 
“last unexplored area” in discovering the impact of a first-line coronary anatomic 
investigative strategy. Whether competing risks from non-cardiac conditions obscure the 
benefits of invasive management, and at what level of competing risk this occurs, remains a 
commonplace clinical dilemma. All available evidence demonstrates that patients with 
acute myocardial injury and type 2 MI experience a very high rate of all-cause mortality, in 
part related to associated non-coronary competing risks. The outcome and effect size used 
in the planning of this study have been selected to reflect patient relevant improvements in 
median survival of greater than 1 year with coronary anatomic investigation. Arguments for 
the routine use of angiography include: 1. Clarification of diagnosis through identification 
of unrecognized T1MI (plaque rupture) versus fixed coronary obstructions versus no 
coronary obstruction and; 2. Documentation of coronary pathology as a focus for 
revascularization and pharmacological therapy which have provided benefits in other acute 
presentations of coronary artery disease. (3,19) Arguments against the early anatomical 
investigation include: 1.  The comorbidities of these patients are too great and aggressive 
intervention could be regarded as futile; 2.  The risk of bleeding may be pronounced with 
the addition of heparin, aspirin and P2Y12 inhibitors. 3. The time-course benefits of 
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benefit afforded by improved diagnostic precision may be overwhelmed by the impact of 
non-coronary competing risks. Better quantification of cardiac risk, competing risk and 
their interaction with the possible benefits of anatomical investigation requires more robust 




Evolution in troponin assays has increased the complexity of the clinical estimation of 
coronary risk. The efficacy of anatomical coronary investigation among T2MI patients with 
high competing risks has not been adequately investigated and remains a point of 
substantial clinical equipoise, despite the greater prevalence of these patients than T1MI. 
Prospectively incorporating risk assessment into the decision algorithm will assist the 
translation of current therapies into effective outcomes and inform a large evidence-gap in 
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Table and Figure Legends 
Table 1: Patient inclusion and exclusion criteria 
Table 2: Study Outcomes Definitions 
Figure 1: Contrasting cardiac and non-cardiac outcomes between Type 2 and Type 1 MI. 
Figure 2: Study Schematic.  
 
Footnote: APACHE: Acute Physiology, Age and Chronic Health Evaluation, GRACE: 
Global Registry for Acute Coronary Events: WCC: White Cell Count, CRP: C-reactive 
protein, BNP: Brain Natiutretic Peptide, Mx: management 
 
Figure 3: Summary of diagnostic uncertainty, cardiac risk, competing risk and evidence of 
benefit with anatomic investigation and management of coronary artery disease.  
Footnote: STE: ST Segment Elevation, NSTE: non-ST Segment Elevation. PROMISE: 
PROspective Multicenter Imaging Study for Evaluation of chest pain,  SCOT-HEART: 
Scottish COmputed Tomography of the HEART, COURAGE: Clinical Outcomes Utilizing 
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Table 1: Patient Selection Criteria 
Patient Inclusion Criteria 
The study will enrol in-hospital patients with at least one elevated (“rule-in”) troponin result using the local laboratory 
standards (Troponin T or I, with test sensitivity as implemented locally) defined as either (also see troponin pattern 
section): 
i. Troponin T (Roche Elecsys): >52ng/L 
ii. Troponin I (Abbott Architect, Dimension Vista, Beckman Access): ≥5 times the assay-specific upper 
limit of normal 
and: 
 
a) A clinical presentation consistent with an acute clear non-coronary alternative diagnosis (see section below) 
N.B.: In all cases medical stabilization of patient prior to angiography will be required. 
b) Patient is 18 years of age or older; and 
c) Patient is willing to give his/her written informed consent; 
Documentation of “acute non-coronary” presentation:    
For trial eligibility, all patients must have an unequivocal intercurrent diagnosis. Specifically: 
d) Sepsis: Clinical evidence of a fever and/or a raised white cell count plus an elevation in C-reactive protein above 
the local laboratories reference limit and: 
a. Pneumonia: Cough, shortness of breath, positive sputum culture and radiological changes consistent 
with pneumonia on chest imaging 
b. Urosepsis: frequency, urgency or dysuria, with leukocytes in urinalysis and positive urine microscopy 
and culture 
c. Septicaemia: systemic symptoms of fevers, chills or sweats, and positive blood cultures thought not to 
be a contaminant. 
d. Systemic Inflammatory Response Syndrome (SIRS): With 3 or more of: 
i. Temperature, <36 °C (96.8 °F) or >38 °C (100.4 °F) 
ii. Heart rate, >90 beats/min 
iii. Respiratory rate, >20/min or PaCO2<32 mmHg 
iv. While bleed cell count, <4x109/L, >12x109/L, or 10% bands 
e) Anaemia: haemoglobin <10mg/dL on at least 2 samples within 48 hours 
f) Thyrotoxicosis: TSH below the lower limit of normal 
g) Atrial tachycardias: evidence of sustained narrow complex tachycardia (Atrial fibrillation, atrial flutter, SVT) 
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tachycardia). 
h) Respiratory failure with an arterial oxygen tension <8 kPa (<60mmHg) and clinical signs of 
respiratory failure lasting >20 min. 
i) Arterial hypertension with a systolic blood pressure >160 mm Hg with or without concomitant left 
ventricular hypertrophy identified by echocardiography or electrocardiogram. 
j) Recent non-cardiac surgery, defined as surgical procedure requiring regional and general anaesthesia within 7 
days prior to enrolment  
k) Traumatic fractured neck of femur demonstrated on x-ray, within the prior 7 days  
l) Acute kidney injury requiring dialysis or causing severe renal impairment (creatinine >150mmol/L) patients 
where dialysis remains a therapeutic consideration. 
 
Patient Exclusion Criteria 
a. Patients with clinically-defined T1MI: i.e. a rise and/or fall in troponin with at least 1 result above the 99th 
percentile of normal, with/without ECG changes consistent with ischaemia, and NO evidence of intercurrent 
illness. 
b. Patients with ST-segment elevation on the presenting ECG or new LBBB 
c. Haemodynamic instability including hypotension (Systolic BP<90mmHg, or requiring inotrope support), 
acute kidney injury where creatinine levels are not stable 
d. Patients with a prior angiogram within the last 6 months, regardless of the presence or absence of 
documented coronary artery disease on that investigation. 
e. New York Heart Association Class II-IV heart failure or Killip Class II-IV 
f. Symptomatic angina with a Canadian Cardiovascular Society class II or more classification 
g. Extensive frailty or co-morbidity in whom the treating physicians are unwilling to undertake a coronary 
angiogram (e.g. severe renal impairment in a patient unwilling to consider dialysis), or where life-expectancy 
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Death form any cause 
CV Mortality CV death will be defined as any death resulting from acute myocardial infarction (MI), cardiogenic shock, 
cardiac arrhythmia/sudden cardiac death, heart failure/acute pulmonary oedema, stroke, CV procedures, CV 
hemorrhage, and any other CV causes which are documented as an antecedent cause of death on the death 
certificate.  
New/Recurrent MI* Acute myocardial injury with clinical evidence of acute myocardial ischaemia and with detection of a rise 
and/or fall of cTn values with at least one value above the 99th percentile URL and at least one of the 
following; 
○ Symptoms of myocardial ischaemia; 
○ New ischaemic ECG changes; 
○ Development of pathological Q waves; 
○ Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality in a pattern consistent with an ischaemic aetiology; 
○ Identification of a coronary thrombus by angiography or autopsy (not for types 2 or 3 MIs). 
Post mortem demonstration of acute athero-thrombosis in the artery supplying the infarcted myocardium 
(meets type 1 MI criteria).  
Evidence of an imbalance between myocardial oxygen supply and demand unrelated to acute athero-
thrombosis (meets type 2 MI criteria).  
Cardiac death in patients with symptoms suggestive of myocardial ischaemia and presumed new ischaemic 
ECG changes before cTn values become available or abnormal (meets type 3 MI criteria).  
 
MI:  In pat ients whom troponin i s  e levated  and s table (<20% varia t ion)  
If troponin values are stable or falling, then myocardial infarction diagnosis requires a ≥ 20% increase (and > 
URL) in troponin between the last sample recorded prior to randomisation and a further sample taken 3-6 hours 
later  
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If troponin values continue to rise after randomisation, there must be evidence of a ≥ 20% increase between the 
last sample recorded prior to randomisation AND documentation of one of the following:  
 
o New ischaemic ECG changes 
o Angiographic findings of a coronary thrombus  
MI fol lowing PCI  
An MI after PCI will be defined as:  
 Elevation of cTn values (>5X 99th percentile URL) in patients with normal baseline values (≤99th 
percentile URL) or a >5X increase in cTn values and a change of ≥20% if the baseline values are 
elevated and are stable (≤20% variation) or falling. In addition to at least one of the following: 
o New ischemic ECG changes;  
o Imaging evidence of loss of viable myocardium that is presumed to be new and in a pattern 
consistent with an ischemic etiology; 
o Angiographic findings consistent with a procedural flow-limiting complication such as 
coronary dissection, occlusion of a major epicardial artery or graft, side-branch occlusion-
thrombus, disruption of collateral flow or distal embolization. 
MI fol lowing CABG  
In participants undergoing CABG, diagnosis of MI will require:  
 Elevation of cTn (>10X 99th percentile URL) in patients with normal baseline cTn values (≤99th 
percentile URL) or a >10X increase in cTn values and a change of >20% if the baseline values are 
elevated and are stable (≤20% variation) or falling. In addition to at least one of the following:  
o Development of pathological Q waves; 
o Angiographic findings consistent with a procedural flow-limiting complication such as 
coronary dissection, occlusion of a major epicardial artery or graft, side-branch occlusion-
thrombus, disruption of collateral flow or distal embolization;  
o Imaging evidence of loss of viable myocardium that is presumed to be new and in a pattern 
consistent with an ischemic etiology; 
 
Unstable Angina   
Ischemic discomfort (angina, or symptoms thought to be equivalent) ≥ 10 minutes in duration occurring: 
 At rest, or 
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capacity 
AND 
Prompting an unscheduled hospitalization within 24 hours of the most recent symptoms. 
Hospitalization is defined as an admission to an inpatient unit or a visit to an emergency department 
that results in at least a 24 hour stay (or a change in calendar date if the hospital admission or 
discharge times are not available).  
AND 
At least one of the following: 
a. New or worsening ST or T wave changes on resting ECG (in the absence of cofounders, such 
as LBBB or LVH) 
i. Transient ST elevation (duration <20 minutes) 
New ST elevation at the J point in two contiguous leads with the cut-point: ≥0.1mV 
in all leads other than leads V2-V3 where the following cut-points apply: 
≥0.2mV in men ≥40 years (≥0.25mV in men <40 years) or 
≥0.15mV in women 
ii. ST depression and T-wave changes 
New horizontal or down-sloping ST depression ≥0.05mV in two continuous leads 
with prominent R wave or R/S ratio >1.  
The above ECF criteria illustrate patterns consistent with myocardial ischemia. It is 
recognized that lesser ECG abnormalities may represent an ischemic response and 
may be accepted under the category of abnormal ECG findings. 
 
b. Definite evidence of inducible myocardial ischemia as demonstrated by: 
i. An early positive exercise stress test, defined as ST elevation or ≥2mm ST 
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OR 
ii. Stress echocardiography (reversible wall motion abnormality) OR 
iii. Myocardial scintigraphy (reversible perfusion defect), OR 
iv. MRI (myocardial perfusion deficit under pharmacologic stress) 
v. AND believed to be responsible for the myocardial ischemic symptoms/signs 
 
c. Angiographic evidence of new or worse ≥70% lesion (≥50% for left main lesion) and/or 
thrombus in an epicardial coronary artery that is believe to be responsible for the myocardial 
ischemic symptoms/signs. 
 
d. Need for coronary revascularization procedure (PCI or CABG) for the presumed culprit 
lesion(s). This criterion would be fulfilled if revascularization was undertaken during the 




Negative cardiac troponin and no evidence of acute MI 
Unplanned hospital 
admission 
Non-elective coronary revascularization; cerebrovascular accidents; atrial or ventricular arrhythmias; 
congestive cardiac failure without MI; as documented by a hospital discharge summary at 30 days, 12 months 
and 24 months.  
Bleeding  TIMI Major/minor/minimal bleed:  
 Major: Overt clinical bleeding (or documented intracranial or retroperitoneal hemorrhage) associated 
with a drop in hemoglobin of greater than 5g/dl (50g/l) or a hematocrit of greater than 15% (absolute). 
 Minor: overt clinical bleeding associated with a fall in hemoglobin of 3g/dL to 5g/dL (50g/l) or a 
hematocrit of 9% to less than or equal to 15% (absolute). 
 Minimal: Any clinically overt sign of hemorrhage (including imaging) that is associated with a <3 g/dl 
decrease in the hemoglobin concentration or <9% decrease in the hematocrit 
 
GUSTO Bleeding Classification 
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compromise and requires intervention 
 Moderate: Bleeding that requires blood transfusion but does not result in hemodynamic compromise 
 Mild: Bleeding that does not meet criteria for either severe or moderate bleeding 
 
ACUITY Bleeding Classification 
 Intracranial or intraocular 
 Reduction in Hb of ≥ 4.0 g/dL without an overt source of bleeding, or of ≥ 3.0 g/dL with an overt 
source of bleeding 
 Use of any blood product transfusion 
 Hematoma ≥ 5cm in diameter, re-operation for bleeding, access site hemorrhage requiring intervention 
 
Bleeding events will also be classified using the BARC Bleeding Classification (20)  
Health Economic 
Evaluation 
o Measures of in-hospital care: stress testing, echocardiography, coronary angiography, cardiac medications 
at discharge consistent with guidelines  
o Health-related quality of life (EQ-5D) at 30 days, 12 and 24 months  
Resource utilisation over 24 months: Medicare data among consenting patients using Medical Benefits 
Schedule (MBS), medication use from Pharmaceutical Benefits Schedule (PBS) and inpatient admissions 
from the AN-Diagnosis Related Group (DRG) version 6.0. 
* N.B. troponin elevations will undergo blinded adjudication for MI to confirm event time.  All in-hospital MIs occurring during the index presentation will 
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Figure 2: Study schematic 
APACHE: Acute Physiology, Age and Chronic Health Evaluation, GRACE: Global Registry for Acute Coronary Events: WCC: 
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Figure 3: Summary of diagnostic uncertainty, cardiac risk, competing risk and evidence of benefit with anatomic investigation and 
management of coronary artery disease. (2,3,19,21-23) 
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